Procalcitonin: A Marker for the Diagnosis and Follow-Up of Patients with Medullary Thyroid Carcinoma

Algeciras‐Schimnich, Alicia; Preissner, Carol M.; Theobald, Jannick; Finseth, Mary S.; Grebe, Stefan K.

doi:10.1210/jc.2008-1862

Cited by 75 publications

(67 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…centrations of PCt show much better stability under all conditions, with concentrations decreasing to no more than 10% when stored at room temperature [30]. Thus, it was suggested that basal serum PCt could be a promising additional diagnostic test to exclude MTC [29][30][31][32][33][34].…”

Section: Mfnb In Thyroid Nodules With Mtc J Endocrinol Metab 2017;7(mentioning

confidence: 99%

Modified Fine-Needle Aspiration Biopsy for Calcitonin, Procalcitonin and Carcinoembryonic Antigen Levels in the Diagnosis of Thyroid Nodules With Medullary Thyroid Carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Mfnb In Thyroid Nodules With Mtc J Endocrinol Metab 2017;7(mentioning

confidence: 99%

Modified Fine-Needle Aspiration Biopsy for Calcitonin, Procalcitonin and Carcinoembryonic Antigen Levels in the Diagnosis of Thyroid Nodules With Medullary Thyroid Carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The titles and abstracts of these articles were reviewed, and nine original papers were selected; their fulltext versions were then retrieved, and their references lists were scanned (Bihan et al 2003, Bolko et al 2003, Algeciras-Schimnich et al 2009, Kaczka et al 2010, 2012, Walter et al 2010, Kratzsch et al 2011, Giovanella et al 2013, Machens et al 2014. These papers were published from 2003 to 2014, and they were all original articles (Table 1).…”

Section: Eligible Articlesmentioning

confidence: 99%

“…These papers were published from 2003 to 2014, and they were all original articles (Table 1). Almost all of the studies were from European researchers (Bihan et al 2003, Bolko et al 2003, Kaczka et al 2010, 2012, Walter et al 2010, Kratzsch et al 2011, Giovanella et al 2013, Machens et al 2014, and one was conducted by US investigators (Algeciras-Schimnich et al 2009). Some of these studies used ProCT (Bihan et al 2003, Giovanella et al 2013, Machens et al 2014 in the preoperative diagnosis of MTC, whereas the remaining ones (Bihan et al 2003, Bolko et al 2003, Kaczka et al 2010, 2012, Walter et al 2010, Kratzsch et al 2011 measured ProCT during follow-up of patients who had been previously treated for MTC.…”

Section: Eligible Articlesmentioning

confidence: 99%

“…Seven papers (Bihan et al 2003, Bolko et al 2003, Algeciras-Schimnich et al 2009, Kaczka et al 2010, 2012, Walter et al 2010, Kratzsch et al 2011 reported ProCT measurement in MTC patients during follow-up after surgery. A total of 265 MTC cases, of which 114 involved cured patients and 151 were recurrent/persistent cases, were reported.…”

Section: Use Of Proct For the Postoperative Detection Of Recurrent Mtcmentioning

confidence: 99%

“…A total of 265 MTC cases, of which 114 involved cured patients and 151 were recurrent/persistent cases, were reported. The most relevant paper was published by Algeciras-Schimnich et al (2009); it collected data on a series of 133 MTC cases (42 cured and 91 active), and 83 out of 91 (91.2%) of the recurrent MTCs had ProCT of over 0.15 ng/ml, whereas none of the cured MTCs had positive ProCT (specificity 100%). Among the active MTCs, those with stable disease had the lowest mean ProCT levels (3.6 ng/ml), patients with recurrent/metastatic disease had the highest mean value (241.7 ng/ml), and patients with newly diagnosed cancer had intermediate levels (13.8 ng/ml).…”

Section: Use Of Proct For the Postoperative Detection Of Recurrent Mtcmentioning

confidence: 99%

See 2 more Smart Citations

Procalcitonin for detecting medullary thyroid carcinoma: a systematic review

Trimboli¹,

Seregni²,

Treglia³

et al. 2015

Endocrine-Related Cancer

View full text Add to dashboard Cite

The aim of the present study was to perform a systematic review of published studies to provide a robust estimation of the use of procalcitonin (ProCT) as a diagnostic marker of medullary thyroid carcinoma (MTC), with particular focus on its specificity and negative predictive value in excluding MTC. A comprehensive computer literature search was conducted to find relevant published articles on the topic. We used a search algorithm based on a combination of the terms 'medullary,' 'thyroid,' and 'ProCT.' The search was updated until February 2015. To expand our search, references of the retrieved articles were also screened. A total of 39 articles were retrieved, of which nine original papers published from 2003 to 2014 were selected for the review. Some of these studies used ProCT in the preoperative diagnosis of MTC, whereas others measured ProCT during the follow-up of patients who had been previously treated for MTC. Other laboratory measurements were performed in some of the included studies. The results of the majority of the studies indicate that ProCT measurement appears to be a very promising and reliable serum marker for the diagnosis of MTC, and it is not inferior to calcitonin (CT). The sample handling is less laborious, and in the few CT-negative cases reviewed, the assay had even greater sensitivity. It would be worthwhile to establish cutoff levels using larger patient series, because we speculate that this assay could potentially replace CT measurement in the future.

show abstract

Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer

Walter

Meier

Radimerski

et al. 2009

Cancer

View full text Add to dashboard Cite

BACKGROUND: Procalcitonin has been well established as an important marker of sepsis and systemic infection. The authors evaluated the diagnostic and predictive value of calcitonin and its prohormone procalcitonin in medullary thyroid cancer. METHODS: The authors systematically explored the ability of calcitonin and procalcitonin to identify medullary thyroid cancer and predict the endpoints local recurrence and distant metastases, as well as the progression-free survival. Patients with C-cell hyperplasia; patients after thyroidectomy for differentiated thyroid cancer, goiter, or Graves disease; and healthy subjects served as controls. The study was performed in accordance with the Reporting Recommendations for Tumor Marker Prognostic Studies of the National Cancer Institute. RESULTS: Sixtynine medullary thyroid cancer patients and 96 controls were included (median observed interval: 10.9 years [range, 1.4-47.5 years]; 981.8 patient-years). The 1-year, 5-year, 10-year, and 20-year recurrence rates were 9%, 34%, 45%, and 56%, respectively. Calcitonin had a higher diagnostic accuracy for detecting medullary thyroid cancer than procalcitonin ( The results of the current study indicate a superior diagnostic accuracy of calcitonin and an independent predictive value of the procalcitonin:calcitonin ratio. These findings may lead to improved diagnostic and therapeutic strategies for medullary thyroid cancer patients. Cancer 2010;116:31-40.

show abstract

Procalcitonin: A Marker for the Diagnosis and Follow-Up of Patients with Medullary Thyroid Carcinoma

Abstract: A strong correlation was observed between PCT and CT levels in patients with MCT. Given PCT's greater analytical stability, we conclude that it represents a promising complementary MTC tumor marker.

Cited by 75 publications

References 19 publications

Modified Fine-Needle Aspiration Biopsy for Calcitonin, Procalcitonin and Carcinoembryonic Antigen Levels in the Diagnosis of Thyroid Nodules With Medullary Thyroid Carcinoma

Modified Fine-Needle Aspiration Biopsy for Calcitonin, Procalcitonin and Carcinoembryonic Antigen Levels in the Diagnosis of Thyroid Nodules With Medullary Thyroid Carcinoma

Procalcitonin for detecting medullary thyroid carcinoma: a systematic review

Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer

Contact Info

Product

Resources

About